Nasdaq
$26.04▲ 0.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.15BShares out 44.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 9.17After-hours26.09.18 05:104Ownership#●●●
Avalyn Pharma Inc.
Insider Robert J. Meyer of Avalyn Pharma Inc. reported a change in beneficial ownership of securities as of September 15, 2026. This filing serves as a formal disclosure of insider transaction activity via Form 4.…more
$26.04+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17After-hours26.09.18 05:053Ownership
Avalyn Pharma Inc.
Avalyn Pharma Inc. has filed a Power of Attorney authorizing the CEO and CFO to execute and file Forms 3, 4, and 5 on behalf of the undersigned officer, director, or beneficial owner in accordance with Section 16(a) of the Securities Exchange Act. This filing serves as an administrative measure to ensure timely compliance with regulatory reporting requirements for insider transactions.…more
$26.04+0.31%vs prev closeView filingShare - 9.16After-hours26.09.17 05:138-KKey event
Avalyn Pharma Inc.
Avalyn Pharma Inc. appointed Dr. Robert Meyer as an independent director to its Board of Directors, effective September 15, 2026. Dr. Meyer, who brings extensive experience in FDA regulatory strategy and the life sciences industry, was granted an initial stock option to purchase 31,182 shares of common stock.…more
$26.04+0.31%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.21Pre-market26.09.21 22:04#●●●#●●●
Avalyn Pharma Publishes Phase 1 Results for IPF Treatment AP02
Avalyn Pharma has published detailed Phase 1 clinical trial results for its inhaled IPF treatment, AP02, validating its targeted drug delivery approach. The company is currently conducting a Phase 2 trial with topline data expected in late 2027.…more
$26.04+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.21Pre-market26.09.21 22:00
●●●●●●●● ●●●●● ●●●●●●
Avalyn Pharma has published Phase 1 clinical data demonstrating the safety and lung-targeted delivery profile of its inhaled IPF treatment, AP02. The company is currently conducting a Phase 2 trial with topline results expected in late 2027.…more
$26.04+0.31%vs prev close - 9.16After-hours26.09.17 05:01
●●●●●●●● ●●●●● ●●●●●●
Avalyn Pharma has appointed Dr. Robert J. Meyer, a former senior FDA official and pulmonary expert, to its Board of Directors. This appointment aims to strengthen the company's regulatory expertise as it advances its clinical-stage respiratory therapy programs.…more
$26.04+0.31%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report